Deutsche Bank 'Remains Cautious' on Valeant (VRX); Analyst Maintains Hold Rating
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Citron Research to Discuss Valeant Pharma (VRX) at 12:30PM on Bloomberg
October 22, 2015 10:45 AM EDTCitron Research said it will be on Bloomberg TV at 12:30PM ET to discuss Valeant Pharma (NYSE: VRX) which follows yesterday's scathing report and drastic sell-off.
Bloomberg's live feed can be found here:... More
Valeant Pharma (VRX) Resumes Free-Fall; Down 15%
October 22, 2015 9:44 AM EDTValeant Pharma (NYSE: VRX) is back testing the $100 level again. Shares down 15% currently.
Today's BMO Capital downgrade, highlighted earlier, is certainly not helping.
... MoreValeant's (VRX) Buy Rating Affirmed at BofA/Merrill Lynch
October 22, 2015 7:26 AM EDTBofA/Merrill Lynch maintained a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $290. Analyst Sumant S. Kulkarni said he continues to monitor concerns related to improper pricing and alleged irregularities in financial reporting, but he believes Valeant presents an "enhanced... More
BMO Capital Downgrades Valeant Pharmaceuticals (VRX) to Market Perform; Cannot Defend the Specialty Pharmacy Structure
October 22, 2015 7:00 AM EDTBMO Capital downgraded Valeant Pharmaceuticals (NYSE: VRX) from Outperform to Market Perform with a price target of $141.00, saying they cannot defend the specialty pharmacy structure.
Analyst Alex Arfaei commented, "Based on our understanding, ~10% of Valeants revenues come from specialty pharmacies. While other companies also use specialty pharmacies, the structure of Valeants network seems different. In... More
Shkreli Says He's Long Valeant Pharma (VRX), Short Allergan (AGN)
October 21, 2015 3:53 PM EDTMartin Shkreli said on twitter that he is long Valeant Pharma (NYSE: VRX) and short Allergan (NYSE: AGN) as a hedge.... More
Valeant Pharma (VRX) Calls Citron Report 'Erroneous'
October 21, 2015 1:40 PM EDTValeant Pharma (NYSE: VRX) issued the following statement following earlier accusations of fraud by short seller Citron Research, which has sent shares down 39.5% today:
Philidor Rx Services is a pharmacy licensed in Pennsylvania and also provides back-end services, including call center,... MoreCitron Research says it has a 'smoking gun' on Valeant Pharma (VRX)
October 21, 2015 10:10 AM EDT(Updated - October 21, 2015 10:22 AM EDT)
Citron Research says it has a "smoking gun" on Valeant Pharma (NYSE: VRX) and lowered its price target to $50.
In a report entitled "Could this be the Pharmaceutical Enron?", Citron Research discusses the recently reported relationship with Philidor RX.
Citron also notes a court filing made by a company called R&O Pharmacy, filed with the California District Court in September, in which this small regional pharmacy... More
